f(x) Immune Diagnostics, Inc. Announces New CEO For Immediate Release: Candler, NC, December 19, 2017 —f(x) Immune Diagnostics, Inc. today announced that its board of directors has appointed Michael Sowinski, as the Company’s new Chairman of the Board and CEO, effective immediately. “The board is delighted that Mike will lead f(x) Immune into the next stage of growth,” said Socrates Choumbakos, CFO and board
North Carolina Company Completes License Deal Important to the Global Effort Against Pneumococcal Infections For Immediate Release: Candler, NC, November 10, 2017 —f(x) Immune Diagnostics, Inc. has obtained the worldwide exclusive license to provide testing kits, services, and manufacturing of fully human monoclonal antibodies against Streptococcus pneumoniae. The license was obtained from Pamlico Biopharma, Inc. and is based on patents and technologies from the
Congratulations to UNC-Asheville for successfully completing a competitive grant process through the North Carolina Biotechnology Center.